A Look at Upcoming Innovations in Electric and Autonomous Vehicles DEA Raises Psychedelic Quotas, Leaves Marijuana Numbers Pending Rescheduling

DEA Raises Psychedelic Quotas, Leaves Marijuana Numbers Pending Rescheduling

The DEA has filed a draft Federal Register notice proposing 2027 production quotas for Schedule I and II substances, and the headline move is a sharp increase in allowable manufacturing of MDMA and ibogaine tied to expanding clinical research. For marijuana, though, the agency is holding steady at 2026 levels for now - and flagging that a separate rulemaking is coming once it sorts out how to handle cannabis products that have already moved to Schedule III.

Psychedelics Get a Significant Bump

Ibogaine production would jump from 210 grams this year to 12,002 grams in 2027 - a scale-up that reflects, in DEA's own framing, "the increased level of research and clinical trials" targeting PTSD and depression. MDMA quotas would rise from 12,000 grams to 33,296 grams. Psilocybin and psilocyn, while not called out in the narrative text, also see proposed increases: psilocybin from 50,000 to 60,000 grams, psilocyn from 80,000 to 93,600 grams. DEA ties the expansion to executive orders from the Trump administration, including an April order aimed at expanding psychedelic research and access. For companies manufacturing under DEA registration for clinical-trial supply, this is a meaningful operational signal - more raw material headroom means fewer bottlenecks for sponsors running Phase 2 and Phase 3 work.

Marijuana Quotas Stay Flat - For Now

Here's the catch for cannabis operators watching this process: the new filing keeps Schedule I marijuana-related quotas unchanged from 2026 - 6,675,000 grams of cannabis, 1,000,000 grams of extract, 1,523,040 grams of delta-9-THC, and 1,166,130 grams of other THC. That's not because nothing is happening. It's because DEA is still working through the mechanics of Attorney General Todd Blanche's order moving state-licensed medical marijuana and FDA-approved cannabis products to Schedule III. New drug codes have already been assigned for the rescheduled categories, and DEA says it's registering manufacturers and distributors who'll handle those substances while it figures out which datasets should govern future quota-setting. In practice, this means the Schedule I numbers published this week only cover marijuana still used for federally sanctioned research - not the broader supply chain feeding state medical or adult-use markets.

What Operators and Suppliers Should Watch

A separate Federal Register notice will address Schedule III quotas once DEA settles on a methodology - and that's the one with real consequence for licensed cultivators, processors, and labs supplying FDA-approved cannabinoid products. Quota-setting under Schedule III could reshape how manufacturers forecast production capacity, structure wholesale agreements, and plan for 280E tax relief that rescheduling is expected to bring. A parallel hearing is also underway on shifting non-medical marijuana to Schedule III, adding another layer operators need to track. None of this changes state-level compliance obligations - seed-to-sale tracking, COA requirements, and packaging rules remain governed by individual state programs regardless of federal scheduling status. But the quota mechanics matter for any business positioned to manufacture FDA-approved cannabis products once that pathway solidifies.

A 30-Day Comment Window

Once the notice is formally published, DEA will take public comments for 30 days. That's a narrow window, and it's worth flagging for trade associations, manufacturers, and research sponsors who want input on both the psychedelic increases and the marijuana quota gap. Rescheduling has moved marijuana policy forward on paper; the quota mechanics are what will determine how quickly that translates into operational reality for licensed businesses waiting on federal clarity.